World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
132
Citations
84570
World Ranking
2278
National Ranking
1286

Nicholas J. Vogelzang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nicholas J. Vogelzang sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 984 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nicholas J. Vogelzang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nicholas J. Vogelzang sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 132 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nicholas J. Vogelzang is affiliated with the University of Nevada Reno in the United States and has contributed extensively to the field of medicine, specifically within oncology and pulmonary and respiratory medicine. Their research output includes significant work in related subfields such as surgery, radiology, nuclear medicine and imaging, and cancer research.

Their scientific contributions focus on key topics including:

  • Prostate Cancer Treatment and Research
  • Cancer Immunotherapy and Biomarkers
  • Radiopharmaceutical Chemistry and Applications
  • Bladder and Urothelial Cancer Treatments
  • Cancer Genomics and Diagnostics
  • Renal Cell Carcinoma Treatment
  • PARP Inhibition in Cancer Therapy

They have collaborated frequently with several researchers, including:

  • Maha Hussain
  • David I. Quinn
  • Celestia S. Higano
  • Ian M. Thompson
  • Petros Grivas

Major venues for their publications include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Genitourinary Cancer
  • Clinical Cancer Research
  • The Lancet Oncology

Selected recent publications are as follows:

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, 2020, The Lancet
  • Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration, 2020, Journal of Clinical Oncology
  • Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study, 2020, Clinical Cancer Research
  • Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, 2023, Journal of Clinical Oncology
  • Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study, 2021, The Lancet Oncology

Their publication record spans over 265 works primarily in medicine, with a pronounced focus on oncology-related disciplines.

Best Publications

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle

  • Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

    Nicholas J. Vogelzang;James J. Rusthoven;James Symanowski;Claude Denham

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu

  • Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

    H. Barton Grossman;Ronald B. Natale;Catherine M. Tangen;V.O. Speights

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

    Gregory A. Curt;William Breitbart;David Cella;Jerome E. Groopman

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

    Philip W. Kantoff;Susan Halabi;Mark Conaway;Joel Picus

  • Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

    John P. Leonard;Matthew L. Sherman;Gerald L. Fisher;Lynn J. Buchanan

  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

    Thomas Powles;Peter H. O'Donnell;Christophe Massard;Hendrik Tobias Arkenau

  • Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

    Susan Halabi;Eric J. Small;Philip W. Kantoff;Michael W. Kattan

  • Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline

    D. Andrew Loblaw;Katherine S. Virgo;Robert Nam;Mark R. Somerfield

  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

    Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler

  • Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

    James E. Herndon;Mark R. Green;A. Phillippe Chahinian;Joseph M. Corson

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

    Matthew D. Galsky;José Ángel Arranz Arija;Aristotelis Bamias;Ian D. Davis

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

Frequent Co-Authors

David I. Quinn
David I. Quinn University of Southern California
Maha Hussain
Maha Hussain Northwestern University
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio
Celestia S. Higano
Celestia S. Higano University of Washington
Mark J. Ratain
Mark J. Ratain University of Chicago
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Catherine M. Tangen
Catherine M. Tangen Fred Hutchinson Cancer Research Center
Chris Parker
Chris Parker Institute of Cancer Research
Walter M. Stadler
Walter M. Stadler University of Chicago
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the medical field isn't limited to pursuing a traditional M.D. There are flexible and affordable online alternatives for those interested in healthcare careers. Many nurses aim to advance professionally by completing one of the rn to bsn cheapest programs, which allow registered nurses to earn a bachelor’s degree quickly and affordably.

If you're considering a graduate-level path but do not yet have nursing experience, direct entry np programs for non nurses online can be a fast pathway to becoming a nurse practitioner without a prior nursing background.

For those starting out and seeking accessible entry points into nursing, there are easy nursing schools to get into that help make this career choice more attainable.

Not everyone interested in medicine works directly with patients; administrative roles are crucial too. Consider training through one of the medical billing and coding online schools to start a rewarding career in healthcare support.

Best Scientists Citing Nicholas J. Vogelzang

Trending Scientists

Recently Published Articles